Highlights of Worldwide Views on SGLT2 Inhibitors to Optimize Glucose Homeostasis in Type 2 Diabetes Mellitus

Endocrinology
Curriculum:
Axis SGLT2
Credits:
0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
November 18, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Endocrinologists, primary care physicians, scientists, and other healthcare professionals who manage the care of patients with type 2 diabetes mellitus

Relevant Terms:

Type 2 diabetes

James R. Gavin III, MD, PhD
 

James R. Gavin III, MD, PhD
Emory University School of Medicine
Atlanta, GA
 

James R. Gavin III, MD, PhD is Clinical Professor of Medicine at Emory University School of Medicine in Atlanta, Georgia, and Clinical Professor of Medicine at the Indiana University School of Medicine, Indianapolis, Indiana.  He currently serves as Chief Executive Officer and Chief Medical Officer of Healing Our Village, Inc.  Dr. Gavin belongs to a number of national organizations, is a past president of the ADA and was voted Clinician of the Year in Diabetes by the ADA in 1991. He has served on many advisory boards and on the editorial boards of the American Journal of Physiology and the American Journal of Medical Sciences. In addition, he is national program director of the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Dr. Gavin is also Chairman Emeritus of the National Diabetes Education Program and a past member of the Board of Scientific Councilors for the Intramural Research Program of NIDDK at the NIH. He serves as chairman of the Data Safety Monitoring Board for the VA Cooperative Diabetes Study (VADT).
 
Dr. Gavin has published more than 225 articles and abstracts in such publications as Science, Journal of Applied Physiology, Diabetes, and the American Journal of Physiology. He is co-author of two books: Healing Our Village: A Self-Care Guide for Diabetes Control and Dr. Gavin's Health Guide for African Americans.  He earned his doctorate in biochemistry from Emory University and his Doctor of Medicine degree from Duke University School of Medicine, Durham, North Carolina.
 
1. Review the role of the kidney in blood glucose regulation in type 2 diabetes mellitus
2. Validate the rationale for SGLT2 inhibitor therapy based on its unique glycosuria-based mechanism of action
3. Determine the appropriate use of SGLT2 therapy in patients with type 2 diabetes that are otherwise healthy or exhibit higher blood glucose concentration
4. Integrate emerging evidence on novel SGLT2 inhibitors into the treatment paradigm for patients with type 2 diabetes mellitus

Purpose
The goal for this program is to begin to close educational and practice gaps by providing clinicians with the latest clinical evidence on the appropriate use of SGLT2 inhibitors, as well as benefits and risks to optimize glycemic control throughout type 2 diabetes mellitus care continuum.
 
Accreditation Statement
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
 
Credit Designation
Endocrine Society designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
How To Claim Credit
Credits will be awarded automatically upon passing each activity post-test with a grade of 70% or better and completion of each activity evaluation.
 
Statement of Independence
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.
 
Disclosure Policy
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
 
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

 
The following Special Program Committee members who planned and/or reviewed content for this activity reported no relevant financial relationships:
 
Jeffrey Boord, MD, MPH
 
The following faculty reported relevant financial relationships:
 
James R. Gavin III, MD, PhD, reported a financial interest/relationship or affiliation in the form of: Advisor, Abbott Diabetes Care, Boehringer Ingelheim, Intarcia Therapeutics, Vivus Pharmaceuticals, Inc.; Consultant, AstraZeneca Pharmaceuticals LP, Janssen Pharmaceuticals, Inc., sanofi US; Speakers' Bureau, AstraZeneca Pharmaceuticals LP, Lilly-Boehringer Ingelheim Diabetes Alliance, Janssen Pharmaceuticals, Inc.
 
The following Special Program Committee members who planned and/or reviewed content for this activity reported relevant financial relationships:
 
Endocrine Society staff associated with the development of this program reported no relevant financial relationship and/or conflicts of interest.
 
AXIS Medical Education staff associated with the development of this program reported no relevant financial relationship and/or conflicts of interest: Linda King, MS, Deb Middleton, BS, and Diedrea White, BA.
 
Disclaimer
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
 
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
 
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
 
Policy on Unlabeled/Off-Labeled Use
Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation.
 
Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
 
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.